1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Aslan Bullish On Once-Monthly Dosing For Eblasakimab In Atopic Dermatitis

 
• By Jessica Merrill

A Phase IIb trial testing the IL-13 inhibitor in atopic dermatitis demonstrated solid efficacy when dosed once every four weeks, but the market is competitive and dominated by Sanofi/Regeneron’s Dupixent.

raise the bar
Aslan says it raised the efficacy bar in AD; investors aren't as sure • Source: Shutterstock

ASLAN Pharmaceuticals Pte Ltd believes it has a competitive dosing profile for its IL-13 inhibitor eblasakimab in atopic dermatitis and other allergic inflammatory conditions, based on new Phase II results. But the company still needs to run Phase III trials and, even if the drug is eventually approved, it will face a fiercely competitive market dominated by Sanofi/Regeneron Pharmaceuticals, Inc.’s entrenched mega-blockbuster IL-4/IL-13 inhibitor Dupixent (dupilumab).

Key Takeaways
  • Phase IIb trial shows the highest dose of the IL-13 inhibitor eblasakimab in AD compares favorably to what was seen in clinical trials testing Dupixent.
  • Eblasakimab could be differentiated with once monthly dosing, but is behind rivals.
  • Bigger trials are needed, and Aslan plans to advance eblasakimab into Phase III

Eblasakimab is the first biologic to demonstrate a competitive efficacy profile with once-monthly dosing in moderate-to-severe atopic dermatitis at 16 weeks compared to biologics dosed every two weeks, the company said

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

More from R&D

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.